All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
You're logged in! Click here any time to manage your account or log out.
You're logged in! Click here any time to manage your account or log out.

ASPEN trial: Zanubrutinib versus ibrutinib for patients with Waldenström macroglobulinemia

Bookmark this article

During the American Society of Clinical Oncology (ASCO) Annual Meeting, the Lymphoma Hub was pleased to speak to Constantine Tam, Peter MacCallum Cancer Centre, Melbourne, AU. In this video, he discusses the phase III ASPEN trial, where treatment with the two Bruton's tyrosine kinase (BTK) inhibitors, zanubrutinib and ibrutinib, were compared in patients with Waldenström macroglobulinemia.

Constantine Tam, explains the mechanism of action of the two drugs, the patient response rates and safety results of the two treatment arms. He also explains that although the trial did not meet its primary endpoint (very good partial response), zanubrutinib showed greater tolerability and safety compared to ibrutinib.

ASPEN trial: zanubrutinib versus ibrutinib for patients with Waldenström macroglobulinemia

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Your opinion matters

Which treatment do you select for patients with follicular lymphoma after multiple relapses?
0 votes - 6 days left ...


Subscribe to get the best content related to lymphoma & CLL delivered to your inbox